Project Grant R01CA293996
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$735K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
The National Cancer Institute (NCI) awarded a 5-year, $3,537,456 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Regents of the University of California, San Francisco (UCSF) to conduct research on optimizing subtype-specific breast cancer screening and prevention. The project aims to develop improved risk assessment models that can predict the specific type of breast cancer a woman is likely to develop, in order to tailor screening and prevention...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $622,329 to Virginia Commonwealth University (VCU) to develop an inhibitor called PDZ1I and evaluate its ability to prevent metastasis and sensitize triple-negative breast cancer (TNBC) to chemotherapies. The award, which runs from August 2024 to July 2029, supports experiments to formulate PDZ1I into a nanocrystal (PDZ1I-nano) for clinical use, characterize how PDZ1I impacts the immune...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports a $644,804 research project titled "Advancing Breast Cancer Risk Assessment for Black Women." The project aims to develop and validate a novel deep learning-based breast cancer risk assessment tool focused on Black women, leveraging digital breast tomosynthesis (DBT) imaging data. Key objectives include: Developing a DBT-driven...
The U.S. National Cancer Institute (NCI) awarded a $450,000 Project Grant under the CFDA 93.396 Cancer Biology Research program to The Research Foundation for the State University of New York, doing business as Stony Brook University. The project, titled "Topological Methods for Breast Tissue Quantification," aims to develop advanced algorithms and analytical techniques using topological data analysis (TDA) to extract and interpret fine-grained structural information from breast...
The National Cancer Institute awarded a $684,333 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Trustees of Columbia University in the City of New York. The project, titled "Integrating Breast Cancer and Cardiovascular Disease Risk to Explore Decision-Making for Chemoprevention Among Racially/Ethnically Diverse Women at High Risk for Breast Cancer," aims to evaluate if patient and provider decision support that juxtaposes breast cancer...
This $432,304 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will fund research to develop enhanced cancer risk prediction models for underrepresented Black and Hispanic populations. The key products to be delivered include: Novel data integration methods that can effectively leverage diverse data sources, including electronic health records and biobanks, while addressing challenges around data privacy and the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will provide $169,932 from September 2024 to July 2029 to The Trustees of Columbia University in the City of New York to advance proteomics technologies for cancer research. The award will enable the recipient's Proteomics and Macromolecular Crystallography Shared Resource to enhance its capabilities by developing innovative methodologies, including automated deep proteomic profiling for...
The National Cancer Institute (NCI) awarded a $566,523 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Colorado-Denver. The 5-year grant, awarded on Dec 5, 2024, will fund research to identify interception targets in persistent lung pre-malignant lesions (PMLs) and determine the effects of prevention agents on persistence pathways. The research aims to develop a precision approach for lung cancer prevention by intercepting PMLs most...
This federal Project Grant award, valued at $407,321 and awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research), supports research to investigate alternative splicing and isoform expression as mediators of the genetic etiology of breast cancer. The key objectives are to: Quantify isoform expression and alternative splicing events in breast tissue using novel transcript assemblies from long-read RNA sequencing data. This will involve benchmarking statistical...